Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff
Celldex Therapeutics will halt development of barzolvolimab for eczema after Phase 2 trial failure, but plans approval filing for chronic hives. NChroma Bio will cut staff and explore strategic alternatives after halting hepatitis B drug testing. Isomorphic Labs partners with Merck for cancer drug development. Teva Pharmaceuticals' R&D chief is leaving, but analysts remain confident. VitriVax raised $87M for Lyme disease vaccine development.
How this was made
The 30-second read
Why it matters
Collectively, the disclosures shift probability-weighting across multiple pipeline assets: eczema development is being stopped, hepatitis B testing is paused pending strategic review, while new partnered oncology work and new vaccine funding improve forward optionality for other programs.
Market read
Traders can reassess near-term pipeline risk for CLDX and NCHM, while factoring financing and partnership catalysts for VITR and ISOM/MRK, and managing transition risk for TEVA.
What to watch
For nChroma, strategic alternatives could lead to asset sale or partnership that changes risk quickly; for Isomorphic-Merck, the lack of disclosed targets and economics may delay meaningful repricing until more scientific and financial details emerge.
Background
The article is a multi-company biotech roundup covering Celldex’s eczema Phase 2 setback, nChroma’s hepatitis B program halt and restructuring, an Isomorphic-Merck oncology collaboration, a Teva executive departure, and VitriVax’s Series C financing for a Lyme vaccine.
Ticker impact
Celldex will stop developing barzolvolimab in eczema after Phase 2 results failed to meet its internal hurdle rate for continued development.
Likely downward pressure as investors reprice the eczema franchise and reduce probability-weighted value from barzolvolimab in that market.
The article states a development stop in eczema based on Phase 2 underperformance versus an internal hurdle, which is a direct risk reduction for that indication.
Merck is named as the partner in Isomorphic Labs' new cancer collaboration, covering development costs for resulting small-molecule programs.
Neutral to slightly positive, with investors focusing on whether the collaboration meaningfully expands Merck's oncology pipeline.
The article does not disclose program targets, milestones, or expected economics for Merck, making directional impact uncertain.
Teva's R&D chief and chief medical officer Eric Hughes is leaving, with David Gardiner temporarily covering the role until a permanent successor is named.
Likely limited market impact unless investors interpret the exit as signaling internal issues; otherwise, shares may stabilize on continuity.
The article highlights a surprise leadership change but includes analyst support and does not cite operational failures or guidance changes.
Market effects
Biopharma sentiment may tilt toward higher selectivity in immunology and hepatitis B development, while oncology partnerships and vaccine financing remain supportive signals.
Primarily US-listed biotech sentiment; limited direct cross-asset impact expected.
Oncology collaboration and vaccine development are globally relevant, but the article provides no cross-border regulatory or pricing details.
Counterpoint
Analysts may argue eczema Phase 2 failures are not decisive for barzolvolimab’s broader platform, especially given planned chronic hives filing and prior late-stage success.
Key entities
- companyCelldex Therapeutics
Stops barzolvolimab eczema development after Phase 2 underperformance versus internal hurdle rate.
- companynChroma Bio
Halts hepatitis B lead program and evaluates strategic alternatives amid staff cuts and restructuring.
- companyIsomorphic Labs
Announces a cancer-focused small-molecule collaboration with Merck with milestones and royalties.
- companyMerck & Co.
Partner covering development costs for programs arising from the Isomorphic collaboration.
- companyTeva Pharmaceutical
R&D chief and CMO Eric Hughes exits; David Gardiner temporarily covers the role.





